Atlas Trials

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Clinical trial NCT04836832 · WITHDRAWN

Trial details

NCT number
NCT04836832
Sponsor
Narendranath Epperla
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Nodal Marginal Zone LymphomaRecurrent Splenic Marginal Zone LymphomaRefractory Follicular LymphomaRefractory Indolent Non-Hodgkin LymphomaRefractory Marginal Zone LymphomaRefractory Nodal Marginal Zone LymphomaRefractory Splenic Marginal Zone Lymphoma
Start date
2022-07-01
Primary completion
2023-12-31
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.